AWA
IBRX icon

Arete Wealth Advisors’s ImmunityBio IBRX Stock Holding History

Arete Wealth Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
114,920
-471,814
-80% -$3.57M 0.07% 225
2026
Q1 		$4.5M Buy
+586,734
New +$4.02M 0.34% 76

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arete Wealth Advisors's IBRX Position: Q2 2026 in Review

Arete Wealth Advisors reduced its ImmunityBio (IBRX) stake by 80% in Q2 2026, selling an estimated $3.57M and leaving 114,920 shares worth $1.01M. The position accounts for 0.07% of the portfolio, ranked #225.

Arete Wealth Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.5M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Arete Wealth Advisors held 114,920 shares of ImmunityBio worth $1.01M as of Q2 2026.
  • Arete Wealth Advisors sold 471,814 ImmunityBio shares in Q2 2026, an estimated $3.57M.
  • ImmunityBio made up 0.07% of Arete Wealth Advisors's portfolio in Q2 2026, its #225 holding.
  • Arete Wealth Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Arete Wealth Advisors's ImmunityBio position peaked at $4.5M in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Arete Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.